Shire, dissatisfied with the success – but not “resounding success” – of its amphetamine/amino acid combination Vyvanse, is developing the drug (which recently failed trials as an antidepressant) as a treatment for binge-eating.
Shire, dissatisfied with the success – but not “resounding success” – of its amphetamine/amino acid combination Vyvanse, is developing the drug (which recently failed trials as an antidepressant) as a treatment for binge-eating.
Oh man. Reading the business press when they report on drugs, especially psych drugs, is like reading the minutes of the latest meeting of Murder, Inc.
Report comment
Shire, dissatisfied with the success – but not “resounding success” – of its amphetamine/amino acid combination Vyvanse, is developing the drug (which recently failed trials as an antidepressant) as a treatment for binge-eating
Yeah, well they could sell it alongside olanzapine, now there’s a market!
Report comment
If a drug cannot out-perform placebo (not a difficult task, considering half the data is tossed out); it’s tried for another condition.
And the ones that get approved by the FDA are slightly modified once the cash cow runs dry. They are “re-treaded” and marketed for something else.
Marcia Angell, M.D. –
http://www.youtube.com/watch?v=ouF3ISihHLM
Duane
Report comment
Wasn’t it recently reported that studies are now showing a connection between stimulant use and obesity and diabetes later in life?
Report comment